IPO
IPO
Best Performers
Forthcoming Issues
Closed Issues
New Listings
Current Issues
IPO Performance
IPO News
IPO Analysis
Basis of Allotment
Draft Prospectus
  HOME  >  IPO  >   IPO SNAPSHOT
IPO Snapshot    
Goldline Pharmaceutical Ltd.
Issue Open Date 12-May-26  
Issue Closing Date 14-May-26  
Application Money 100  
Allotment Money  
Price Band 41 - 43  
Minimium Application No. 6000  
Issue Size (Shares) 1968000  
Market Lot 1.00  
Objective
1. Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our Company; and2. General corporate purposes.
Category No. of Shares No. of Shares Subscription Ratio
  Offered / Reserved Bid For  
Non-Institutional Investors   528000   648333000   1227.90  
Qualified Institutional Buyers   540000   97317000   180.22  
Retail Individual Investors   900000   793038000   881.15  
Business Description
We are engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Our product portfolio is organized into five distinct segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness.
more...
Promoter's Holding
Total Share Capital   5499982  
Offered to Public   1968000  
Promoter's Holding (Pre-Issue)   79.7  
Promoter's Holding (Post-Issue)    
Address
103
F-1
Leela Apartment
Shilpa Hsg Society
Near Saptagiri Nagar
Shanidham
Narendra Nagar
Nagpur ,
Maharashtra ,
440015
Phone: 712-278 6666
Email: info@goldlinepharma.in
Website: www.goldlinepharma.in
Registrar
Bigshare Services Pvt Ltd
G 10 Left Wing Amruta Village
Opp: Yashoda Hospital
Raj Bhavan Road
Somajiguda
Hyderabad
Listed at
BSE
Lead Manager
Cumulative Capital Pvt Ltd
Promoters
Amol Laxmikant Mujumdar
Swapan Premprakash Khandelwal
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.